Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial (IDH2) antibody

Antigen: Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial (IDH2)

Synonyms: IDPm, Idh-2, E430004F23, IDH2, idh2, zgc:55485, wu:fb33c06, wu:fk31e05, wu:fq43b01, F6P23.14, F6P23_14, ISOCITRATE DEHYDROGENASE SUBUNIT 2, NAD+ DEPENDENT ISOCITRATE DEHYDROGENASE SUBUNIT 2

Clonality: Monoclonal (5F11)

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)

Certificates: ISO 9001:2008

Catalog no.: ABIN396597

Additional Information

Alternative name: IDH2

Gene ID: 3418

UniProt: NP_002159

Immunogen: IDH2 (NP_002159, 354 a.a. ~ 452 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 K

Isotype: IgG1 kappa

Clone: 5F11

Description: Other names: ICDM, IDH, IDHM, IDP, mNADPIDH isocitrate dehydrogenase 2 (NADP+), mitochondrial

Characteristics: Purified Mouse Monoclonal Antibody (Mab)

Specificity: IDH2 (NP_002159, 354 a.a. ~ 452 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.

Molecular Weight: 50909 DA

Comments:

Background: Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the mitochondria. It plays a role in intermediary metabolism and energy production. This protein may tightly associate or interact with the pyruvate dehydrogenase complex.

Application Details

Application Notes: ELISA ~~ 1ug/ml~3ng/ml Western blot ~~ 1:500~1000 Immunohistochemistry ~~ 1.5ug/ml

Purification: Purified

Buffer: Clear, colorless solution in phosphate buffered saline, pH 7.2 .

Storage: Maintain refrigerated at 2-8 deg C for up to 6 months. For long term storage store at -20 deg C in small aliquots to prevent freeze-thaw cycles

Research Area: Metabolism, Cell Structure

Restrictions: For Research Use only

Images

Immunoperoxidase of monoclonal antibody to IDH2 ( Cat # AT2479a ) on formalin-fixed paraffin-embedded human colon. [antibody concentration 3 ug/ml] Detection limit for recombinant GST tagged IDH2 is approximately 0.03ng/ml as a capture antibody.

anti-Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial (IDH2) antibody (Image 2)

Publications

Product: Paschka, Schlenk, Gaidzik et al.: "IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 28, Issue 22, pp. 3636-43, 2010 (PubMed).

Lopez, Reitman, Solomon et al.: "IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain." in: Biochemical and biophysical research communications, Vol. 398, Issue 3, pp. 585-7, 2010 (PubMed).

Boissel, Nibourel, Renneville et al.: "Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 28, Issue 23, pp. 3717-23, 2010 (PubMed).

Sellner, Capper, Meyer et al.: "Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations." in: European journal of haematology, Vol. 85, Issue 5, pp. 457-9, 2010 (PubMed).

Rocquain, Carbuccia, Trouplin et al.: "Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias." in: BMC cancer, Vol. 10, pp. 401, 2010 (PubMed).